Particle.news
Download on the App Store
4 ARTICLES
·
last wk.

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Targeting acetylated tau, the candidate has entered an FDA-cleared first-in-human trial with Sanofi set to lead later development.

Sanofi logo at the company's headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier
Shares in Sanofi rose 2% to €82.27 ($96.87) at market open on 16 December. LCV via Shutterstock.com.
Image

Overview

  • ADEL will receive an $80 million upfront payment, with additional development and commercial milestones that could bring the total to $1.04 billion, plus tiered royalties up to double-digit percentages.
  • The agreement grants Sanofi exclusive worldwide rights to ADEL-Y01 and its related backup compounds for development and commercialization.
  • ADEL-Y01 is a humanized monoclonal antibody designed to bind tau acetylated at Lysine-280 (acK280) to inhibit propagation of toxic tau species while preserving normal tau function.
  • The therapy is being evaluated in a global Phase 1 first-in-human study under a U.S. FDA IND, with the trial listed as NCT06247345.
  • ADEL discovered and advanced the program using its protein modification platform and has co-developed it with Oscotec since 2020, while Sanofi publicly endorsed the mechanism as a differentiated approach.